Novel Treatment Advances and Approaches in Management of HIV

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of HIV

These are archives of live webinars held between December 9 to December 18, 2020.
If you participated in any of the live webinars, you are not eligible
to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

This activity is valid from January 1, 2021 to January 1, 2023

This series is supported by educational grants from
ViiV Healthcare

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
HIV is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). HIV infection leads to low levels of CD4+ T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 people in the US aged 13 years and older are living with HIV infection and an estimated 6,955 people died in 2019. Fortunately, several new therapies have become available recently, and more are set to become available soon.

Integrating the Latest Data and Guidelines in the Management of HIV: Strategies for Optimizing Clinical and Economic Outcomes

1. Examine the clinical burden of HIV, including factors that contribute to poor prognosis and increased costs
2. Compare and contrast new and emerging antiretroviral therapies (ART) based on the latest evidence for their efficacy, safety, and adherence potential
3. Apply recent clinical trial data to identify appropriate patient populations for new and emerging 2-drug regimens, including long-acting ART
4. Explore the role of newer therapies for heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection
5. Evaluate patient-specific factors, including age, comorbidities, concomitant medications, and adherence challenges, in making decisions about HIV therapy selection

Improving Patient Adherence and Quality of Life in HIV: A Closer Look at the Role of Novel Long-Acting Injectable and Implantable ART Formulations

1. Examine challenges to patient adherence, administration and quality of life in the management of HIV
2. Identify strategies to optimize patient-centered HIV medication therapy management and adherence support
3. Evaluate strategies to monitor and manage adverse events associated with new and emerging therapies in HIV in order to improve patient adherence and quality of life
4. Analyze the role of novel long-acting injectable and implantable ART formulations

Comparative Effectiveness and Payer-Provider Coordination in HIV: What Does Managed Care Need to Know About New and Emerging Therapies?

1. Examine the economic burden of HIV, including factors that contribute to poor prognosis and increased costs
2. Compare and contrast new and emerging antiretroviral therapies (ART) based on the latest evidence for their efficacy, safety, and adherence potential
3. Assess approaches currently utilized by third party payers to manage costs associated with the care of patients with HIV
4. Discuss the managed care considerations of new and emerging therapies by exploring where these agents may fit into current HIV management paradigm
5. Align managed care decisions with updated guidelines and evidence on initial ART selection and ART switching based on patient-specific factors, including comorbidities, concomitant medications, age, adherence, and patient preferences